- Market Capitalization, $K 29,130,636
- Shares Outstanding, K 656,687
- Annual Sales, $ 1,549 M
- Annual Income, $ 728,930 K
- 60-Month Beta 0.89
- Price/Sales 18.72
- Price/Cash Flow 37.65
- Price/Book 8.81
|Period||Period Low||Period High||Performance|
| || |
+3.06 (+7.32%)since 06/23/21
| || |
+8.06 (+21.90%)since 04/23/21
| || |
+9.11 (+25.48%)since 07/23/20
ALXN vs. GMAB: Which Stock Is the Better Value Option?
Genmab A/S (Nasdaq: GMAB) and Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) announced today that the companies have entered into an oncology research and development collaboration. Together, the companies...
Seagen (SGEN) lags estimates for earnings and revenues in the first quarter of 2021. Shares lose ground in after-hour trading.
The FDA accepts Seagen (SGEN) and Genmab's BLA for tisotumab vedotin under a priority review to treat recurrent/metastatic cervical cancer. A verdict is pending on Oct 10, 2021.
Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) seeking...
--- BLA Submission Supported by Positive Pivotal innovaTV 204 Trial Results Presented at the European Society of Medical Oncology Virtual Congress 2020 -
The European Medicines Agency accepts Seagen (SGEN) and Astellas Pharma's marketing application for enfortumab vedotin for treating adult patients with advanced/metastatic urothelial cancer.
Seagen (SGEN) submits a BLA to the FDA for accelerated approval of tisotumab vedotin in patients with recurrent/metastatic cervical cancer, whose disease has progressed on or after chemotherapy.
Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval...
Biotech stocks attracted maximum attention in 2020 due to the COVID-19 pandemic and a worldwide scramble to develop vaccines. Favorable news surrounding vaccines has boosted confidence generally that biotech...
|3rd Resistance Point||45.00|
|2nd Resistance Point||44.85|
|1st Resistance Point||44.61|
|1st Support Level||44.22|
|2nd Support Level||44.07|
|3rd Support Level||43.83|